CMS Proposed Rule Enhances Medicare Advantage & Impact on PBMs
The Centers for Medicare & Medicaid Services (CMS) has proposed a rule, stemming from the Consolidated Appropriations Act of 2026, that aims to enhance Medicare Advantage (MA) operations and impact Pharmacy Benefit Managers (PBMs) with a focus on transparency and accountability.
The newly proposed rule seeks to revise provider directory requirements and adjust cost-sharing mechanisms for low-income individuals enrolled in Medicare Part D. This initiative underscores a broader regulatory push to streamline the functionality and transparency of PBMs, which have been under scrutiny for their role in drug pricing and access. Amidst this backdrop, a bipartisan proposal in the U.S. House also aims to delay the 340B Rebate Model Pilot Program by two years, shifting its launch to 2029. This program's delay addresses concerns about the financial pressures on safety-net providers who must initially cover the entire medication cost before obtaining rebates.
Implications for Medicare Advantage Enrollees
According to the Kaiser Family Foundation (KFF), 74% of Medicare Advantage enrollees, roughly 20.9 million individuals, have pre-existing conditions that could hinder their eligibility for Medigap coverage if they switch to Medicare Fee-For-Service outside designated trial periods. This situation stresses the need for agents and brokers to assist clients in understanding their coverage options and the potential barriers they face.
Market Trends and Legislative Proposals
The individual health insurance market has experienced an 18% enrollment decline from June 2025 to June 2026, translating to approximately 4.6 million fewer enrollees. This significant change calls for strategic adjustments by insurance carriers and agents as they navigate evolving market dynamics. Representatives, including Rob Bresnahan, Jr., are also focusing on legislative measures such as the 340B Rebate Model Delay Act, which proposes a careful evaluation of rebate frameworks and their impact on healthcare providers.
New Initiatives and Frameworks
In parallel with these regulatory efforts, HHS Secretary Robert F. Kennedy's authorization transfer to CMS allows expanded control over excluding providers from Medicare and Medicaid. This shift aims to bolster CMS's regulatory capacity. Additionally, the FDA's Rare Disease Framework Initiative offers promise in streamlining the development of drugs and biologics for rare diseases, emphasizing patient-centric approaches.
| Initiative | Focus | Stakeholders |
|---|---|---|
| 340B Rebate Model Delay Act | Delay start to 2029 | U.S. House |
| Rare Disease Framework | Regulatory clarity for drug development | FDA |
| Health Center Healthy Lifestyle Commitment | Promote preventative care | HHS & HRSA |
Future Developments to Watch
Senate Finance Committee Democrats, spearheaded by Ron Wyden, are soliciting public feedback on long-term care policy proposals designed to boost accessibility and quality of care while prioritizing workforce investments. The outcome of these public comments, open until December 18, 2026, may signal further shifts in the industry, which insurance professionals should watch closely.
As these regulatory and legislative activities unfold, they reflect a concerted effort to improve transparency, patient protection, and access within healthcare policy and insurance markets. Insurance stakeholders must stay informed and agile to navigate and respond to these evolving landscapes effectively.